GlassScriptPhysician profile
Peter Guyon Striegel
NPI 1588753123
$5,890.77
in general payments reported to CMS, 2019-2025
32 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $903 · 2020: $733 · 2021: $1,439 · 2022: $1,091 · 2023: $605 · 2024: $981 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,724.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,591.53 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $896.81 | 2019-2024 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $864.97 | 2019-2023 | Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $386.42 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $377.46 | 2022 | |
| Pfizer INC. | $363.36 | 2019-2025 | |
| Novo Nordisk INC | $323.32 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $275.55 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.32 | 2019-2021 | |
| Allergan, INC. | $110.99 | 2019-2020 | |
| Alkermes, INC. | $62.65 | 2022-2023 | Aristada, Lybalvi |
| Bayer Healthcare Pharmaceuticals INC. | $55.31 | 2021 | |
| Stryker Corporation | $49.93 | 2019-2025 | Regenkit-Tht |
| Astellas Pharma US INC | $30.13 | 2020 | |
| Merck Sharp & Dohme LLC | $28.56 | 2020-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $27.73 | 2021 | |
| Sanofi-Aventis U.S. LLC | $27.72 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.20 | 2022 | |
| Corcept Therapeutics | $22.50 | 2024 | Korlym |
| Endo Pharmaceuticals INC. | $22.44 | 2020 | |
| Horizon Therapeutics Plc | $22.20 | 2023 | Krystexxa |
| Medtronic, INC. | $21.21 | 2023 | Minimed 780g |
| Biohaven Pharmaceuticals, INC. | $19.21 | 2021 | |
| Ibsa Pharma INC. | $18.42 | 2023 | Tirosint, Licart |
| Amneal Pharmaceuticals LLC | $17.00 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $15.72 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.65 | 2021 | |
| Anika Therapeutics, INC. | $15.57 | 2022 | |
| Dexcom, INC. | $14.94 | 2021 | |
| Sanofi Pasteur INC. | $13.87 | 2019 | |
| Amgen INC. | $13.67 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Striegel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.